A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
for
Lupus Nephritis
Location: 11 recruiting locations
Sponsor: Hoffmann-La Roche
Sex: All
Age: 5 - 17
Code: NCT05039619
Phase2, Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)